NCT06243185View on ClinicalTrials.gov

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Recurrent Ovarian Carcinoma
Interventions
DRUG

Dalpiciclib plus letrozole

Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Fengzhi Feng

OTHER